Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Curaleaf Holdings, Inc. (OTCMKTS:CURLF) have been given a consensus rating of “Buy” by the five ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, two have given a buy recommendation and two have issued a strong buy recommendation on the company.

Several research firms have recently weighed in on CURLF. Canaccord Genuity Group raised shares of Curaleaf to a “strong-buy” rating in a research note on Thursday, October 9th. Alliance Global Partners reaffirmed a “buy” rating on shares of Curaleaf in a research report on Monday, December 22nd. ATB Capital raised Curaleaf to an “outperform” rating in a research report on Tuesday, December 2nd. Zacks Research raised shares of Curaleaf from a “strong sell” rating to a “hold” rating in a research note on Thursday. Finally, Atb Cap Markets upgraded shares of Curaleaf from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 2nd.

Curaleaf Trading Up 4.0%

OTCMKTS CURLF opened at $2.62 on Friday. The stock has a market cap of $1.78 billion, a PE ratio of -8.19 and a beta of 0.77. Curaleaf has a 12 month low of $0.68 and a 12 month high of $5.05. The company’s 50-day moving average price is $2.69 and its 200-day moving average price is $2.35. The company has a current ratio of 1.47, a quick ratio of 0.71 and a debt-to-equity ratio of 0.96.

Curaleaf (OTCMKTS:CURLF) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 19.50% and a negative return on equity of 15.57%. Equities research analysts forecast that Curaleaf will post -0.25 earnings per share for the current year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.